Difficulty: Medium
Average Score: 65%
Practice
Your patient with relapsed high-risk neuroblastoma returns to your care after travelling to an outside institution for [131]I-MIBG therapy. In the weeks following [131]I-MIBG therapy, what adverse events directly attributable to this therapy will the patient most likely encounter?
Correct answer
A
Rationale
The correct answer is A: Myelosuppression requiring growth factor and blood product support.
Rationale:
1. [131]I-MIBG therapy targets neuroblastoma cells but can also affect bone marrow, leading to myelosuppression.
2. Myelosuppression can result in low blood cell counts, necessitating growth factors and blood product support.
3. Severe mucositis (B) is not a common adverse event of [131]I-MIBG therapy.
4. Hemorrhagic cystitis (C) is more commonly associated with certain chemotherapies, not [131]I-MIBG.
5. Symptomatic hypothyroidism (D) is a potential long-term side effect, not an immediate consequence following [131]I-MIBG therapy.
Rationale:
1. [131]I-MIBG therapy targets neuroblastoma cells but can also affect bone marrow, leading to myelosuppression.
2. Myelosuppression can result in low blood cell counts, necessitating growth factors and blood product support.
3. Severe mucositis (B) is not a common adverse event of [131]I-MIBG therapy.
4. Hemorrhagic cystitis (C) is more commonly associated with certain chemotherapies, not [131]I-MIBG.
5. Symptomatic hypothyroidism (D) is a potential long-term side effect, not an immediate consequence following [131]I-MIBG therapy.